Particularly, small‐molecule inhibitors against HuR have been employed in various cancers, including Non‐Small Cell Lung Cancer (NSCLC).[42, 43] Furthermore, a modified HuR protein was found to promote retinal pathology in diabetic animals.[44] Additionally, HuR could improve the stabilization of target mRNA levels, contributing to Diabetic Nephropathy (DNP) in kidneys.[45] Herein, TUG1 knockdown and HuR overexpression improved angiogenesis, highlighting a potential avenue for developing targeted drugs that could be used for CIRI treatment. The gene discussed is TUG1; the disease is non-small cell lung carcinoma.